Editas Medicine (EDIT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Editingsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 58/100 (HIGH), 16.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 37.97% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
- EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
- Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
- Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
- Editas Medicine Reports Inducement Grants to New Chief Medical Officer
- Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
- Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
- Editas Medicine to Participate in Upcoming Investor Conferences
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Editas Medicine.
Full EDIT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.